Women with advanced form womb cancer have been given fresh hope after a new treatment was given the green light for ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

A new treatment for advanced endometrial cancer has been approved for use on the NHS, after women with the disease were found ...

In results from a Phase Ib study, Hernexeos showed a 75 percent response rate and more than half of patients responded for at least six months.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Iovance Biotherapeutics IOVA incurred a second-quarter 2025 loss of 33 cents per share, wider than the Zacks Consensus ...

Merck rose 1.17% on a trading day, showcasing a volume of $870M and a 121st rank in activity. Analysts are sending mixed ...

MSD – known as Merck & Co in the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has been ...

How could higher U.S. tariffs on Indian pharmaceutical products impact drug stocks? Seeking Alpha analysts weigh in. Read ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...